Can-Fite BioPharma (NYSE:CANF) Upgraded to Buy at D. Boral Capital

D. Boral Capital upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a buy rating in a research report report published on Wednesday morning, MarketBeat Ratings reports. D. Boral Capital currently has $7.00 target price on the stock.

Separately, HC Wainwright set a $5.00 target price on shares of Can-Fite BioPharma and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Can-Fite BioPharma Stock Up 7.4%

NYSE:CANF opened at $3.64 on Wednesday. Can-Fite BioPharma has a 52 week low of $2.83 and a 52 week high of $23.40. The stock has a market capitalization of $2.38 million, a PE ratio of -2.03 and a beta of 1.09. The stock’s 50-day moving average price is $3.39 and its 200-day moving average price is $4.79.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CANF. Jane Street Group LLC purchased a new position in Can-Fite BioPharma in the 4th quarter worth approximately $41,000. Rhumbline Advisers raised its position in shares of Can-Fite BioPharma by 42.4% during the 1st quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after buying an additional 11,388 shares during the period. Finally, Sabby Management LLC raised its position in shares of Can-Fite BioPharma by 80.3% during the 3rd quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after buying an additional 626,306 shares during the period. 21.00% of the stock is owned by hedge funds and other institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).